Statement: Participants of the primary trial are assigned an intervention depending on their hormone recpetor status.
Primary_evidence: INTERVENTION 1:    Neratinib 240, Prior Trastuzumab   Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment. INTERVENTION 2:    Neratinib 240, No Prior Trastuzumab   Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with no prior trastuzumab treatment.